OncoSupport™

 

The following medications are often used to treat patients with cancer and are currently listed in one of CredibleMed’s three TdP risk categories (category icons defined below):

Anti-cancer Medicine Anti-NauseaAntidepressants Anesthetics
AbarelixChlorpromazineAmitriptylineCocaine
AclarubicinDolasetronAripiprazoleDroperidol
ApalutamideDomperidoneCitalopramPropofol
Arsenic trioxideDroperidolClomipramineSevoflurane
BendamustineGranisetronDesipramine
BortezomibMetoclopramideDoxepin
BosutinibOndansetronEscitalopram
CabozantinibPalonosetronFluoxetine
CapecitabinePromethazineFluvoxamine
CeritinibTropisetronImipramine (melipramine)
CrizotinibMaprotiline
DabrafenibMirtazapine
DasatinibNortriptyline
DegarelixParoxetine
EpirubicinSertraline
Eribulin mesylateTrazodone
Fluorouracil (5-FU)Trimipramine
Inotuzumab ozogamicinVenlafaxine
Lapatinib
Lenvatinib
Leuprolide
Midostaurin
Necitumumab
Nilotinib
Osimertinib
Oxaliplatin
Panobinostat
Pazopanib
Ribociclib
Romidepsin
Sorafenib
Sunitinib
Tamoxifen
Tipiracil and Trifluridine
Toremifene
Vandetanib
Vemurafenib
Vorinostat

Known Risk of TdP - Substantial evidence supports the conclusion that these drugs prolong the QT interval AND are clearly associated with a risk of TdP, even when taken as directed in official labeling.

Possible Risk of TdP - Substantial evidence supports the conclusion that these drugs can cause QT prolongation BUT there is insufficient evidence at this time that these drugs, when used as directed in official labeling, are associated with a risk of causing TdP.

Conditional Risk of TdP - Substantial evidence supports the conclusion that these drugs are associated with a risk of TdP BUT only under certain conditions (e.g. excessive dose, hypokalemia, congenital long QT or by causing a drug-drug interaction that results in excessive QT interval prolongation)

x